Skip to main
RNTX

RNTX Stock Forecast & Price Target

RNTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rein Therapeutics Inc is positioned favorably due to its focus on developing innovative therapies in the orphan pulmonary and fibrosis sectors, which exhibit substantial unmet medical needs. The company's leading candidates, LTI-03 and LTI-01, have demonstrated positive safety and efficacy indicators, with LTI-03 showing increased sRAGE levels in recipients, highlighting its potential impact in treating Idiopathic Pulmonary Fibrosis and loculated pleural effusion. Overall, the company's promising pipeline and potential for realizing a favorable risk-reward opportunity add to the optimism surrounding Rein Therapeutics's stock outlook.

Bears say

Rein Therapeutics Inc has experienced a significant decline in its stock performance, with shares down 50% year-to-date in 2025, substantially underperforming the XBI index's increase of 3.5%. This decline is primarily attributed to the company's decision to pause enrollments in U.S. clinical trials, leading to increased uncertainty regarding the progress of its clinical assets. Additionally, emerging data indicates that lower levels of soluble receptor for advanced glycation end-products (sRAGE) are associated with poor survival rates in patients with Idiopathic Pulmonary Fibrosis (IPF), further complicating the company's prospects in this therapeutic area.

RNTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rein Therapeutics Inc (RNTX) Forecast

Analysts have given RNTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, RNTX has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rein Therapeutics Inc (RNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.